Sphera Funds Management LTD. bought a new stake in Assembly Biosciences Inc (NASDAQ:ASMB) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 100,431 shares of the biopharmaceutical company’s stock, valued at approximately $3,730,000. Sphera Funds Management LTD. owned 0.39% of Assembly Biosciences as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Bank of Montreal Can bought a new position in Assembly Biosciences in the 2nd quarter worth approximately $145,000. TD Asset Management Inc. boosted its holdings in Assembly Biosciences by 20.5% in the 2nd quarter. TD Asset Management Inc. now owns 9,400 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 1,600 shares during the period. Commonwealth Equity Services LLC boosted its holdings in Assembly Biosciences by 14.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 10,497 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 1,365 shares during the period. Alps Advisors Inc. bought a new position in Assembly Biosciences in the 2nd quarter worth approximately $1,169,000. Finally, State of Wisconsin Investment Board boosted its holdings in Assembly Biosciences by 57.3% in the 2nd quarter. State of Wisconsin Investment Board now owns 17,300 shares of the biopharmaceutical company’s stock worth $678,000 after buying an additional 6,300 shares during the period. 84.94% of the stock is owned by institutional investors.
Shares of NASDAQ:ASMB opened at $24.89 on Friday. Assembly Biosciences Inc has a one year low of $20.61 and a one year high of $67.36.
Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.87) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.01) by $0.14. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%. The firm had revenue of $4.29 million during the quarter, compared to the consensus estimate of $3.21 million. Analysts forecast that Assembly Biosciences Inc will post -4.02 EPS for the current fiscal year.
Several research analysts have commented on ASMB shares. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Monday, October 8th. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, November 3rd. Finally, Chardan Capital reissued a “neutral” rating on shares of Assembly Biosciences in a report on Sunday, October 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $52.00.
TRADEMARK VIOLATION NOTICE: “100,431 Shares in Assembly Biosciences Inc (ASMB) Purchased by Sphera Funds Management LTD.” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/08/100431-shares-in-assembly-biosciences-inc-asmb-purchased-by-sphera-funds-management-ltd.html.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Further Reading: LIBOR
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.